Anders Själander

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2118072/publications.pdf

Version: 2024-02-01

44 papers 1,388 citations

430874 18 h-index 36 g-index

44 all docs

44 docs citations

44 times ranked 2291 citing authors

#	Article	IF	CITATIONS
1	Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. European Heart Journal, 2011, 32, 2282-2289.	2.2	218
2	Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. Circulation, 2021, 144, 916-929.	1.6	164
3	Safety and efficacy of well managed warfarin. Thrombosis and Haemostasis, 2015, 113, 1370-1377.	3.4	127
4	Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiology, 2016, 1, 172.	6.1	119
5	Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood, 2013, 122, 1284-1292.	1.4	110
6	Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Annals of Internal Medicine, 2016, 165, 161.	3.9	86
7	Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation. JAMA Cardiology, 2017, 2, 146.	6.1	54
8	Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. British Journal of Haematology, 2015, 169, 683-688.	2.5	49
9	Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. Thrombosis Research, 2015, 136, 216-220.	1.7	37
10	Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. Heart, 2017, 103, 198-203.	2.9	33
11	Populationâ€based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. European Journal of Haematology, 2016, 97, 387-392.	2.2	31
12	Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thrombosis Research, 2018, 167, 113-118.	1.7	29
13	Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PLoS ONE, 2017, 12, e0181000.	2.5	28
14	Thromboembolism, major bleeding and mortality in patients with mechanical heart valves- a population-based cohort study. Thrombosis Research, 2014, 134, 354-359.	1.7	26
15	Mechanical heart valve prosthesis and warfarin – Treatment quality and prognosis. Thrombosis Research, 2014, 133, 795-798.	1.7	25
16	Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: A nationwide population-based study. American Heart Journal, 2016, 181, 1-9.	2.7	24
17	Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study. Thrombosis Research, 2016, 140, 94-99.	1.7	20
18	Venous thromboembolism and cancer risk. Journal of Thrombosis and Thrombolysis, 2017, 43, 68-73.	2.1	20

#	Article	IF	CITATIONS
19	Bleeding complications in venous thrombosis patients on well-managed warfarin. Journal of Thrombosis and Thrombolysis, 2016, 41, 351-358.	2.1	14
20	The impact of socioâ€economic factors on treatment choice and mortality in chronic myeloid leukaemia. European Journal of Haematology, 2017, 98, 398-406.	2.2	14
21	INR variability and outcomes in patients with mechanical heart valve prosthesis. Thrombosis Research, 2015, 136, 1211-1215.	1.7	13
22	Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register. European Journal of Haematology, 2017, 98, 57-66.	2.2	13
23	Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMRâ€"final report from AFTER-SKI. Leukemia, 2021, 35, 2416-2418.	7.2	13
24	Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI. Blood, 2013, 122, 379-379.	1.4	12
25	Warfarin persistence among stroke patients with atrial fibrillation. Thrombosis Research, 2015, 136, 744-748.	1.7	10
26	Predictors for INR-control in a well-managed warfarin treatment setting. Journal of Thrombosis and Thrombolysis, 2019, 47, 227-232.	2.1	10
27	Safety and Efficacy of Bridging With Low-Molecular-Weight Heparin During Temporary Interruptions of Warfarin: A Register-Based Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 961-966.	1.7	9
28	Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the populationâ€based Swedish chronic myeloid leukaemia registry. British Journal of Haematology, 2021, 193, 915-921.	2.5	9
29	Incidence and risk factors of venous thromboembolism in men and women. Thrombosis Research, 2022, 214, 82-86.	1.7	9
30	Warfarin treatment complications do not correlate to cTTR when above 70%. Thrombosis Research, 2015, 136, 1185-1189.	1.7	8
31	Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis. American Heart Journal, 2015, 170, 559-565.	2.7	8
32	Warfarin persistence among atrial fibrillation patients – why is treatment ended?. Cardiovascular Therapeutics, 2016, 34, 468-474.	2.5	7
33	Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Followâ€up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. American Journal of Hematology, 2022, 97, 421-430.	4.1	7
34	Ischemic stroke rates decline in patients with atrial fibrillation as anticoagulants uptake improves: A Swedish cohort study. Thrombosis Research, 2017, 158, 44-48.	1.7	6
35	Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D. CKJ: Clinical Kidney Journal, 2022, 15, 1169-1178.	2.9	6
36	Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants. Journal of Thrombosis and Thrombolysis, 2020, 52, 315-323.	2.1	4

#	Article	IF	CITATIONS
37	Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndromeâ€"A retrospective observational study. PLoS ONE, 2021, 16, e0255009.	2.5	4
38	Triple therapy after PCI – Warfarin treatment quality and bleeding risk. PLoS ONE, 2018, 13, e0209187.	2.5	3
39	Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case–Control Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 151-156.	2.5	3
40	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. Blood, 2015, 126, 343-343.	1.4	3
41	Time to initiation of lipid-lowering drugs for subclinical atherosclerosis: sub-study of VIPVIZA randomized controlled trial, with single-arm cross-over. European Heart Journal Open, 2022, 2, .	2.3	2
42	Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia. Blood, 2015, 126, 1586-1586.	1.4	1
43	No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries. Blood, 2016, 128, 1896-1896.	1.4	O
44	MO758: Warfarin Treatment Quality and Outcomes in Patients with Non-Valvular Atrial Fibrillation and Chronic Kidney Disease Including Patients on Dialysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0